What are the potential benefits of SHuffle Peptide (Elamipretide Context)?

Structural class validating mitochondria-targeted peptide approach. Cardiolipin protection restoring electron transport chain efficiency. Cristae structure preservation essential for supercomplex assembly. Reduced mitochondrial ROS production. Multiple members allow selective targeting of different mitochondrial functions. Inspiration for next-generation mitochondrial therapeutics

What compounds work synergistically with SHuffle Peptide (Elamipretide Context)?

SHuffle Peptide (Elamipretide Context) has been studied alongside MOTS-c, Humanin, CoQ10, NAD+ for potential synergistic effects.

SHuffle Peptide (Elamipretide Context) — Mechanism, Benefits, Research & Synergies

Overview

The Szeto-Schiller (SS) peptide class, developed by Hazel Szeto and Peter Schiller, represents a family of cell-permeable, mitochondria-targeted aromatic-cationic peptides that selectively accumulate 1000-fold in the inner mitochondrial membrane without relying on the transmembrane potential. SS-31 (elamipretide) is the lead compound, but the structural class includes SS-02, SS-19, and SS-20 with varying selectivity for different mitochondrial targets. The SS peptide approach established the principle that cardiolipin-targeting peptides could restore mitochondrial architecture and bioenergetics in aging and disease.

Mechanism of Action

All SS peptides share an alternating aromatic-cationic motif (Phe or Dmt aromatic residues alternating with Arg or Lys cationic residues) that confers mitochondrial membrane affinity via electrostatic and hydrophobic interactions with cardiolipin. Once localized to the inner mitochondrial membrane, SS peptides: (1) protect cardiolipin from oxidation by cytochrome c, restoring electron transfer efficiency; (2) maintain cristae junction structure critical for Complex I/III/IV supercomplex assembly; (3) reduce electron leak and ROS production at Complexes I and III; (4) restore ATP synthase efficiency. The net result is enhanced oxidative phosphorylation, reduced ROS, and improved mitochondrial dynamics.

Potential Benefits

Structural class validating mitochondria-targeted peptide approach
Cardiolipin protection restoring electron transport chain efficiency
Cristae structure preservation essential for supercomplex assembly
Reduced mitochondrial ROS production
Multiple members allow selective targeting of different mitochondrial functions
Inspiration for next-generation mitochondrial therapeutics

Research Dosage Notes

The following reflects doses used in published research studies. This is not medical advice.

See SS-31 (Elamipretide) entry for clinical dosing.

Amino Acid Sequence

SS-31: D-Arg-2',6'-Dmt-Lys-Phe-NH2; SS-02: D-Arg-Dmt-Lys-Phe-NH2 (similar)

Side Effects & Safety

See SS-31 entry for lead compound data

Synergistic Compounds

The following compounds have been studied alongside SHuffle Peptide (Elamipretide Context) for potential complementary or synergistic effects:

MOTS-c HumaninCoQ10NAD+

Learn More

Beginner's GuideNew to peptides? Start here Stacking GuideSynergistic combinations Administration RoutesSubQ, IM, oral, nasal & more Reconstitution CalculatorCalculate exact dosing Peptides vs SARMsFull comparison How Peptides Are MadeSPPS, purification & QC

References & Further Reading

[object Object]
[object Object]

Quick Facts

Molecular Weight	Class ranges 500–1000 Da depending on member
Research Status	SS-31 (elamipretide): Phase II/III clinical trials for heart failure and Barth syndrome. Other SS peptides: preclinical. FDA Breakthrough Therapy designation for Barth syndrome (SS-31).

More Peptides in This Category

SS-31 MOTS-c Humanin 5-Amino-1MQ NAD+ Peptide Complex CJC-1295

SHuffle Peptide (Elamipretide Context)